Overview

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

Status:
Completed
Trial end date:
2018-12-14
Target enrollment:
Participant gender:
Summary
Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
Astellas Pharma Inc
Treatments:
Methylprednisolone
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Tacrolimus